1. Home
  2. VWAV vs SGMT Comparison

VWAV vs SGMT Comparison

Compare VWAV & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VWAV

VisionWave Holdings Inc.

N/A

Current Price

$8.64

Market Cap

155.4M

Sector

Technology

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$5.24

Market Cap

164.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VWAV
SGMT
Founded
2024
2006
Country
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
155.4M
164.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VWAV
SGMT
Price
$8.64
$5.24
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$27.00
AVG Volume (30 Days)
223.6K
830.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.06
$1.73
52 Week High
$18.41
$11.41

Technical Indicators

Market Signals
Indicator
VWAV
SGMT
Relative Strength Index (RSI) 41.48 41.11
Support Level $7.80 $4.92
Resistance Level $9.00 $5.29
Average True Range (ATR) 0.82 0.51
MACD -0.12 -0.06
Stochastic Oscillator 27.42 14.04

Price Performance

Historical Comparison
VWAV
SGMT

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: